DK1414486T3 - Anvendelse af GLP-2 i kombination med et andet terapeutisk middel ved knoglerelaterede sygdomme - Google Patents
Anvendelse af GLP-2 i kombination med et andet terapeutisk middel ved knoglerelaterede sygdommeInfo
- Publication number
- DK1414486T3 DK1414486T3 DK01967517.2T DK01967517T DK1414486T3 DK 1414486 T3 DK1414486 T3 DK 1414486T3 DK 01967517 T DK01967517 T DK 01967517T DK 1414486 T3 DK1414486 T3 DK 1414486T3
- Authority
- DK
- Denmark
- Prior art keywords
- glp
- bone
- combination
- therapeutic agent
- related diseases
- Prior art date
Links
- 101800000221 Glucagon-like peptide 2 Proteins 0.000 title abstract 2
- TWSALRJGPBVBQU-PKQQPRCHSA-N glucagon-like peptide 2 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 TWSALRJGPBVBQU-PKQQPRCHSA-N 0.000 title abstract 2
- 102400000326 Glucagon-like peptide 2 Human genes 0.000 title 1
- 210000000988 bone and bone Anatomy 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 229940124597 therapeutic agent Drugs 0.000 title 1
- 201000002980 Hyperparathyroidism Diseases 0.000 abstract 1
- 102100040918 Pro-glucagon Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0022844A GB0022844D0 (en) | 2000-09-18 | 2000-09-18 | Use of GLP-1 and GLP-2 peptides |
| GB0029920A GB0029920D0 (en) | 2000-12-07 | 2000-12-07 | Use of glp-1 and glp-2 peptides |
| PCT/GB2001/004178 WO2002024214A2 (en) | 2000-09-18 | 2001-09-18 | Use of glp -2 in combination with another therapeutic agent in bone-related and nutrition-related disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1414486T3 true DK1414486T3 (da) | 2010-08-30 |
Family
ID=26245018
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK01982302T DK1326630T3 (da) | 2000-09-18 | 2001-09-17 | Anvendelse af GLP-2-peptider |
| DK01967517.2T DK1414486T3 (da) | 2000-09-18 | 2001-09-18 | Anvendelse af GLP-2 i kombination med et andet terapeutisk middel ved knoglerelaterede sygdomme |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK01982302T DK1326630T3 (da) | 2000-09-18 | 2001-09-17 | Anvendelse af GLP-2-peptider |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US6770620B2 (da) |
| EP (3) | EP1326630B1 (da) |
| JP (2) | JP5161412B2 (da) |
| AT (2) | ATE396738T1 (da) |
| AU (2) | AU2002213925A1 (da) |
| CY (2) | CY1108263T1 (da) |
| DE (2) | DE60134251D1 (da) |
| DK (2) | DK1326630T3 (da) |
| ES (2) | ES2310192T3 (da) |
| PT (2) | PT1326630E (da) |
| WO (2) | WO2002022151A2 (da) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7371721B2 (en) * | 2000-09-18 | 2008-05-13 | Sanos Bioscience A/S | Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes |
| US7186683B2 (en) * | 2000-09-18 | 2007-03-06 | Sanos Bioscience A/S | Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders |
| US20070135345A1 (en) * | 2000-09-18 | 2007-06-14 | Henriksen Dennis B | Use of GLP-2 for the treatment or prevention, of bone-related disorders |
| US20080249016A1 (en) * | 2000-09-18 | 2008-10-09 | Sanos Bioscience A/S | Use of GLP-2 in a combination treatment for bone-related disorders |
| ES2310192T3 (es) * | 2000-09-18 | 2009-01-01 | Sanos Bioscience A/S | Uso de peptidos glp-2. |
| RO120121B1 (ro) * | 2000-12-18 | 2005-09-30 | Elena Ionaşcu | Soluţie injectabilă, cu efect antiinflamator, procedeu de obţinere şi metodă de tratament a bolilor autoimune |
| CA2372450A1 (en) * | 2001-05-10 | 2001-09-19 | Pharmaceutical Partners Of Canada Inc. | Liquid injectable formulation of disodium pamidronate |
| DE10135315A1 (de) * | 2001-07-19 | 2003-01-30 | Bayer Ag | Stents |
| WO2003060071A2 (en) | 2001-12-21 | 2003-07-24 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US20050215552A1 (en) * | 2002-05-17 | 2005-09-29 | Gadde Kishore M | Method for treating obesity |
| CN1320886C (zh) * | 2002-05-17 | 2007-06-13 | 杜克大学 | 安非他酮与抗惊厥药在制备治疗肥胖症的药物的用途 |
| US7812120B2 (en) | 2003-03-21 | 2010-10-12 | Par Pharmaceutical, Inc. | Nasal calcitonin formulations containing chlorobutanol |
| WO2004085471A2 (en) * | 2003-03-24 | 2004-10-07 | Novo Nordisk A/S | Glp-2 derivatives |
| PL2316456T3 (pl) * | 2003-04-29 | 2017-12-29 | Orexigen Therapeutics, Inc. | Kompozycje wpływające na utratę masy zawierające antagonistę opioidów i bupropion |
| EP1870096A3 (en) * | 2003-04-29 | 2011-04-20 | Orexigen Therapeutics, Inc. | Compositions for affecting weight loss |
| WO2004103390A2 (en) | 2003-05-15 | 2004-12-02 | Trustees Of Tufts College | Stable analogs of peptide and polypeptide therapeutics |
| AU2005206139B2 (en) * | 2004-01-13 | 2009-02-26 | Duke University | Compositions of an anticonvulsant and an antipsychotic drug for affecting weight loss |
| US7713959B2 (en) * | 2004-01-13 | 2010-05-11 | Duke University | Compositions of an anticonvulsant and mirtazapine to prevent weight gain |
| EP1748776A1 (en) * | 2004-05-03 | 2007-02-07 | Duke University | Compositions for affecting weight loss |
| PL1877435T5 (pl) * | 2005-05-04 | 2021-09-27 | Zealand Pharma A/S | Analogi peptydu glukagonopodobnego 2 (GLP-2) |
| WO2006135660A2 (en) * | 2005-06-10 | 2006-12-21 | University Of Chicago | Therapies involving lymphotoxin beta receptor |
| DK2135603T3 (da) | 2005-11-22 | 2013-03-25 | Orexigen Therapeutics Inc | Sammensætninger og fremgangsmåder til øgning af insulinsensitivitet |
| WO2007089318A2 (en) * | 2005-11-23 | 2007-08-09 | Orexigen Therapeutics, Inc. | Compositions and methods for reducing food cravings |
| EP2020989A2 (en) * | 2006-05-15 | 2009-02-11 | Wisconsin Allumni Research Foundation | Pulmonary delivery of 1,25-dihydroxyvitamin d3 and co-administration of parathyroid hormone or calcitonin |
| US8916195B2 (en) | 2006-06-05 | 2014-12-23 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
| AU2007319066B2 (en) | 2006-11-08 | 2013-09-19 | Zealand Pharma A/S | Selective glucagon-like-peptide-2 (GLP-2) analogues |
| US8088786B2 (en) | 2006-11-09 | 2012-01-03 | Orexigen Therapeutics, Inc. | Layered pharmaceutical formulations |
| WO2008060964A2 (en) * | 2006-11-09 | 2008-05-22 | Orexigen Therapeutics, Inc. | Unit dosage package and methods for administering weight loss medications |
| CA2682200C (en) | 2007-03-19 | 2015-01-13 | Vita Sciences, Llc | Transdermal patch and method for delivery of vitamin b12 |
| WO2009039991A2 (en) * | 2007-09-11 | 2009-04-02 | Mondobiotech Laboratories Ag | Use of aviptadil as a therapeutic agent |
| US20110144145A1 (en) * | 2008-05-30 | 2011-06-16 | Orexigen Therapeutics, Inc. | Methods for treating visceral fat conditions |
| EP2337585A1 (en) * | 2008-09-19 | 2011-06-29 | Nektar Therapeutics | Polymer conjugates of glp-2-like peptides |
| US8680263B2 (en) | 2008-09-19 | 2014-03-25 | Nektar Therapeutics | Carbohydrate-based drug delivery polymers and conjugates thereof |
| MX344293B (es) | 2008-10-17 | 2016-12-13 | Sanofi Aventis Deutschland | Combinacion de una insulina y un agonista de glp-1. |
| KR20120082003A (ko) * | 2009-09-23 | 2012-07-20 | 바이오키어 인코포레이티드 | 당뇨병 치료용 조성물 및 치료 방법 |
| EP2311486A1 (en) * | 2009-10-07 | 2011-04-20 | Nestec S.A. | GLP-2 for use in intestine and muscle recovery |
| AU2010317995B2 (en) | 2009-11-13 | 2014-04-17 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical composition comprising a GLP-1 agonist, an insulin, and methionine |
| KR101772372B1 (ko) | 2009-11-13 | 2017-08-29 | 사노피-아벤티스 도이칠란트 게엠베하 | Ｇｌｐ-1 효능제 및 메티오닌을 포함하는 약제학적 조성물 |
| US9248123B2 (en) | 2010-01-11 | 2016-02-02 | Orexigen Therapeutics, Inc. | Methods of providing weight loss therapy in patients with major depression |
| AU2011202239C1 (en) | 2010-05-19 | 2017-03-16 | Sanofi | Long-acting formulations of insulins |
| CN103179978A (zh) | 2010-08-30 | 2013-06-26 | 赛诺菲-安万特德国有限公司 | Ave0010用于制造供治疗2型糖尿病用的药物的用途 |
| US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
| KR20140051182A (ko) * | 2011-05-24 | 2014-04-30 | 폴리발러 에스.이.씨. | 특정한 키토산-기재의 나노복합체를 사용하여 ｓｉｒｎａ를 효과적이고 안전하게 전달하기 위한 조성물 및 방법 |
| AU2012300978B2 (en) | 2011-08-29 | 2017-04-27 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for use in glycemic control in diabetes type 2 patients |
| TWI559929B (en) | 2011-09-01 | 2016-12-01 | Sanofi Aventis Deutschland | Pharmaceutical composition for use in the treatment of a neurodegenerative disease |
| US9453064B2 (en) | 2012-05-03 | 2016-09-27 | Zealand Pharma A/S | Glucagon-like-peptide-2 (GLP-2) analogues |
| ES2802048T3 (es) | 2012-06-06 | 2021-01-15 | Nalpropion Pharmaceuticals Llc | Composición para uso en un método para el tratamiento de sobrepeso y obesidad en pacientes con alto riesgo cardiovascular |
| BR112015024659A8 (pt) | 2013-04-03 | 2019-12-17 | Sanofi Sa | formulação farmacêutica aquosa, seu uso, método de tratamento de diabetes mellitus e artigo de fabricação |
| US10493042B2 (en) | 2013-08-01 | 2019-12-03 | University-Industry Cooperation Group Of Kyung Hee University | Method for preventing or treating diabetes mellitus, and method for screening for diabetes mellitus therapeutic agent |
| WO2015016682A1 (ko) * | 2013-08-01 | 2015-02-05 | 경희대학교 산학협력단 | 당뇨병 예방 또는 치료용 약학적 조성물, 당뇨병 예방 또는 치료 방법, 및 당뇨병 치료제 스크리닝 방법 |
| US8969371B1 (en) | 2013-12-06 | 2015-03-03 | Orexigen Therapeutics, Inc. | Compositions and methods for weight loss in at risk patient populations |
| TN2017000235A1 (en) | 2014-12-12 | 2018-10-19 | Sanofi Aventis Deutschland | Insulin glargine/lixisenatide fixed ratio formulation |
| TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患治療 |
| TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患之治療 |
| WO2016205701A1 (en) | 2015-06-19 | 2016-12-22 | University Of Southern California | Enteral fast access tract platform system |
| WO2016205754A1 (en) | 2015-06-19 | 2016-12-22 | University Of Southern California | Compositions and methods for modified nutrient delivery |
| WO2018009778A1 (en) * | 2016-07-07 | 2018-01-11 | Baylor College Of Medicine | Combination of glp-1 and glp-2 for treating or preventing metabolic diseases, disorders and syndromes |
| US10774127B2 (en) | 2016-10-12 | 2020-09-15 | University Of Copenhagen | Peptide dual agonists of GIPR and GLP2R |
| RU2753193C2 (ru) | 2016-12-09 | 2021-08-12 | Зилэнд Фарма А/С | Ацилированные двойные агонисты glp-1/glp-2 |
| US20200261543A1 (en) | 2017-10-12 | 2020-08-20 | University Of Copenhagen | Combination therapy for treatment of bone disorders |
| US20210187077A1 (en) * | 2019-12-23 | 2021-06-24 | Idaho State University | GLP-1 Agonist Conjugates for Sustained Glycemic Control |
| WO2021133087A1 (ko) * | 2019-12-24 | 2021-07-01 | 한미약품 주식회사 | Glp-2 또는 이의 결합체를 포함하는 골 대사성 질환에 대한 예방 또는 치료용 약학적 조성물 |
| CN116437967A (zh) * | 2020-09-25 | 2023-07-14 | 韩美药品株式会社 | 包括对胰高血糖素、glp-1和glp受体全部具有活性的三重激动剂或其缀合物的用于预防或治疗骨病的药物组合物 |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1987006941A1 (en) | 1986-05-05 | 1987-11-19 | The General Hospital Corporation | Insulinotropic hormone |
| EP0464022B1 (en) | 1989-03-20 | 2000-05-31 | The General Hospital Corporation | Insulinotropic hormone |
| DK0512042T3 (da) | 1990-01-24 | 1998-05-11 | Douglas I Buckley | GLP-1-analoger anvendelige ved diabetesbehandling |
| PT101031B (pt) | 1991-11-05 | 2002-07-31 | Transkaryotic Therapies Inc | Processo para o fornecimento de proteinas por terapia genetica |
| US5512459A (en) | 1993-07-20 | 1996-04-30 | Bionebraska, Inc. | Enzymatic method for modification or recombinant polypeptides |
| US5789379A (en) | 1995-04-14 | 1998-08-04 | Allelix Biopharmaceutical Inc. | Glucagon-like peptide-2 analogs |
| US5834428A (en) | 1995-04-14 | 1998-11-10 | 1149336 Ontario Inc. | Glucagon-like peptide-2 and its therapeutic use |
| US5990077A (en) | 1995-04-14 | 1999-11-23 | 1149336 Ontario Inc. | Glucagon-like peptide-2 and its therapeutic use |
| US6184201B1 (en) | 1995-04-14 | 2001-02-06 | Nps Allelix Corp. | Intestinotrophic glucagon-like peptide-2 analogs |
| US5912229A (en) | 1996-03-01 | 1999-06-15 | Novo Nordisk Als | Use of a pharmaceutical composition comprising an appetite-suppressing peptide |
| ATE395359T1 (de) * | 1996-03-01 | 2008-05-15 | Novo Nordisk As | Peptid zur appetitzügelung, dessen zusammensetzungen und verwendung |
| EP2275438A1 (en) | 1996-04-12 | 2011-01-19 | 1149336 Ontario Inc. | Glucagon-like peptide-2 analogs |
| CA2258307C (en) | 1996-07-05 | 2008-02-12 | Novo Nordisk A/S | Method of producing heterologous short chain polypeptides by yeast with impaired yap3 protease |
| US5994500A (en) | 1996-07-19 | 1999-11-30 | 1149336 Ontario Inc. | Antagonists of intestinotrophic GLP-2 peptides |
| EP0929576A1 (en) | 1996-08-30 | 1999-07-21 | Novo Nordisk A/S | Glp-2 derivatives |
| US6011155A (en) * | 1996-11-07 | 2000-01-04 | Novartis Ag | N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
| PT1012186E (pt) | 1996-12-06 | 2002-12-31 | Amgen Inc | Utilizacao de produto(s) da proteina kgf e de produto(s) da proteina glp-2 para a preparacao de um medicamento |
| US5952301A (en) | 1996-12-10 | 1999-09-14 | 1149336 Ontario Inc. | Compositions and methods for enhancing intestinal function |
| EP0946591B1 (en) | 1996-12-13 | 2007-04-04 | Allelix Biopharmaceuticals Inc. | Cloned glucagon-like peptide-2 receptors |
| US6077949A (en) | 1996-12-13 | 2000-06-20 | Allelix Biopharmaceuticals, Inc. | Cloned glucagon-like peptide 2 receptors |
| US6051557A (en) | 1997-05-16 | 2000-04-18 | 1149336 Ontario Inc. | Methods of enhancing functioning of the upper gastrointestinal tract |
| DK0981362T3 (da) * | 1997-05-16 | 2004-03-15 | Ontario Inc 1149336 | Anvendelse af GLP-2-agonister, der forbedrer funktionen af den øvre mavetarmkanal |
| WO1999006059A2 (en) | 1997-07-30 | 1999-02-11 | Board Of Regents, The University Of Texas System | Methods and compositions relating to no-mediated cytotoxicity |
| WO1999014239A1 (de) | 1997-09-12 | 1999-03-25 | Wolf Georg Forssmann | Zusammensetzung zur therapie von diabetes mellitus und fettsucht |
| KR20010034305A (ko) | 1998-01-23 | 2001-04-25 | 한센 핀 베네드 | 효모에서 원하는 폴리펩티드를 만드는 방법 |
| US6803357B1 (en) | 1998-02-02 | 2004-10-12 | New England Medical Center Hospitals, Inc. | Method of regulating glucose metabolism, and reagents related thereto |
| AU2712899A (en) | 1998-02-27 | 1999-09-15 | Novo Nordisk A/S | Glp-2 derivatives with helix-content exceeding 25 percent, forming partially structured micellar-like aggregates |
| WO1999046283A1 (en) | 1998-03-09 | 1999-09-16 | Zealand Pharmaceuticals A/S | Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis |
| FR2777283B1 (fr) * | 1998-04-10 | 2000-11-24 | Adir | Nouveaux composes peptidiques analogues du glucagon-peptide- 1 (7-37), leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| AU7421598A (en) | 1998-05-11 | 1999-11-29 | 1149336 Ontario Inc. | Methods of enhancing functioning of the large intestine |
| IL141471A0 (en) | 1998-08-21 | 2002-03-10 | Point Therapeutics Inc | Regulation of substrate activity |
| US6193997B1 (en) | 1998-09-27 | 2001-02-27 | Generex Pharmaceuticals Inc. | Proteinic drug delivery system using membrane mimetics |
| DE69926007T2 (de) | 1998-10-07 | 2005-12-29 | Medical College Of Georgia Research Institute, Inc. | Glukose-abhängiges, insulinotropisches peptid für die verwendung als osteotropes hormon |
| WO2000028982A2 (en) * | 1998-11-19 | 2000-05-25 | The Board Of Trustees For The University Of Arkansas | Increasing bone strength with selected bisphosphonates |
| DK1137666T5 (da) * | 1998-12-07 | 2009-10-05 | Univ Tulane | GLP-1-analoger |
| CZ295044B6 (cs) * | 1998-12-07 | 2005-05-18 | Societe De Conseils De Recherches Et D'application | Analogy GLP-1, mající kyselinu aminoizomáselnou na pozicích 8 a 35, jejich použití a farmaceutické prostředky je obsahující |
| CO5150173A1 (es) | 1998-12-10 | 2002-04-29 | Novartis Ag | Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv |
| US6271200B1 (en) | 1998-12-21 | 2001-08-07 | Generex Pharmaceuticals Inc. | Proteinic drug delivery system using aerosolized membrane-mimetic amphiphiles |
| EP1147094A1 (en) | 1999-01-15 | 2001-10-24 | Novo Nordisk A/S | Non-peptide glp-1 agonists |
| GB9905416D0 (en) | 1999-03-09 | 1999-05-05 | Allelix Biopharma | Small molecules having GLP-2 like activity |
| US6110949A (en) * | 1999-06-24 | 2000-08-29 | Novartis Ag | N-(substituted glycyl)-4-cyanothiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
| EP1076066A1 (en) | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptides for lowering blood glucose levels |
| WO2001041779A2 (en) | 1999-12-08 | 2001-06-14 | 1149336 Ontario Inc. | Combined use of glp-2 receptor agonist and chemotherapeutic agent in treatment |
| CA2380423A1 (en) * | 2000-05-17 | 2001-11-22 | Bionebraska, Inc. | Peptide pharmaceutical formulations |
| PT1294757E (pt) * | 2000-06-16 | 2007-02-28 | Lilly Co Eli | Análogos do peptídeo-1 do tipo glucagon |
| EP1305338A2 (en) * | 2000-08-02 | 2003-05-02 | Theratechnologies Inc. | Modified peptides with increased potency |
| ES2310192T3 (es) * | 2000-09-18 | 2009-01-01 | Sanos Bioscience A/S | Uso de peptidos glp-2. |
| WO2002066062A2 (en) | 2001-02-01 | 2002-08-29 | Drucker Daniel J | Enhancement of glp-2 activity |
-
2001
- 2001-09-17 ES ES01982302T patent/ES2310192T3/es not_active Expired - Lifetime
- 2001-09-17 DE DE60134251T patent/DE60134251D1/de not_active Expired - Lifetime
- 2001-09-17 EP EP01982302A patent/EP1326630B1/en not_active Expired - Lifetime
- 2001-09-17 WO PCT/EP2001/010714 patent/WO2002022151A2/en active IP Right Grant
- 2001-09-17 PT PT01982302T patent/PT1326630E/pt unknown
- 2001-09-17 JP JP2002526401A patent/JP5161412B2/ja not_active Expired - Fee Related
- 2001-09-17 US US09/954,304 patent/US6770620B2/en not_active Expired - Fee Related
- 2001-09-17 DK DK01982302T patent/DK1326630T3/da active
- 2001-09-17 AU AU2002213925A patent/AU2002213925A1/en not_active Abandoned
- 2001-09-17 EP EP08156283A patent/EP1970072A1/en not_active Withdrawn
- 2001-09-17 AT AT01982302T patent/ATE396738T1/de active
- 2001-09-18 DK DK01967517.2T patent/DK1414486T3/da active
- 2001-09-18 JP JP2002528284A patent/JP5189723B2/ja not_active Expired - Fee Related
- 2001-09-18 ES ES01967517T patent/ES2345874T3/es not_active Expired - Lifetime
- 2001-09-18 PT PT01967517T patent/PT1414486E/pt unknown
- 2001-09-18 WO PCT/GB2001/004178 patent/WO2002024214A2/en active Application Filing
- 2001-09-18 AU AU2001287892A patent/AU2001287892A1/en not_active Abandoned
- 2001-09-18 AT AT01967517T patent/ATE466592T1/de active
- 2001-09-18 EP EP01967517A patent/EP1414486B1/en not_active Expired - Lifetime
- 2001-09-18 DE DE60142084T patent/DE60142084D1/de not_active Expired - Lifetime
-
2003
- 2003-03-18 US US10/391,460 patent/US6943151B2/en not_active Expired - Fee Related
-
2008
- 2008-08-13 CY CY20081100866T patent/CY1108263T1/el unknown
-
2010
- 2010-07-30 CY CY20101100721T patent/CY1110721T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CY1108263T1 (el) | 2014-02-12 |
| JP5161412B2 (ja) | 2013-03-13 |
| US20040082507A1 (en) | 2004-04-29 |
| ES2310192T3 (es) | 2009-01-01 |
| WO2002024214A3 (en) | 2004-02-19 |
| EP1326630A2 (en) | 2003-07-16 |
| DE60142084D1 (de) | 2010-06-17 |
| EP1326630B1 (en) | 2008-05-28 |
| DE60134251D1 (de) | 2008-07-10 |
| CY1110721T1 (el) | 2015-06-10 |
| AU2001287892A1 (en) | 2002-04-02 |
| PT1414486E (pt) | 2010-07-21 |
| EP1970072A1 (en) | 2008-09-17 |
| JP2004524268A (ja) | 2004-08-12 |
| DK1326630T3 (da) | 2008-09-15 |
| US6943151B2 (en) | 2005-09-13 |
| EP1414486B1 (en) | 2010-05-05 |
| WO2002024214A2 (en) | 2002-03-28 |
| US6770620B2 (en) | 2004-08-03 |
| JP2004508410A (ja) | 2004-03-18 |
| WO2002022151A2 (en) | 2002-03-21 |
| AU2002213925A1 (en) | 2002-03-26 |
| US20020037836A1 (en) | 2002-03-28 |
| JP5189723B2 (ja) | 2013-04-24 |
| PT1326630E (pt) | 2008-09-02 |
| ATE396738T1 (de) | 2008-06-15 |
| ES2345874T3 (es) | 2010-10-05 |
| EP1414486A2 (en) | 2004-05-06 |
| WO2002022151A3 (en) | 2003-03-13 |
| ATE466592T1 (de) | 2010-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1414486T3 (da) | Anvendelse af GLP-2 i kombination med et andet terapeutisk middel ved knoglerelaterede sygdomme | |
| DE60121988D1 (de) | Kombinationstherapie mit antidiabetischen und antikonvulsiven mitteln | |
| DE60044041D1 (de) | Exendine zur Glucagon Suppression | |
| ATE486840T1 (de) | Modifizierte formen pharmazeutisch aktiver agenzien und verwendungen dafür | |
| EA200300026A1 (ru) | Аналоги глюкагоноподобного пептида-1 | |
| EE200300212A (et) | Ravimite kombinatsioonid (näiteks kloorpromasiin ja pentamidiin) neoplastiliste haiguste raviks | |
| DK1372650T3 (da) | Kombinationer indeholdende et antidiarrémiddel og en epothilon eller et epothilonderivat | |
| MXPA05008406A (es) | Compuestos de amida tri(ciclo)-sustituida. | |
| ECSP045081A (es) | Derivados de 1,8-naftiridina y su uso para el tratamiento de la diabetes y trastornos relacionados | |
| NO20022528D0 (no) | Kjemiske derivater og deres anvendelse som anti- telomerasemiddel | |
| PT1228028E (pt) | Sais de hidroxieicosatetraeniato, composicoes e metodos para utilizacao no tratamento de perturbacoes da secura ocular | |
| IL155263A0 (en) | Pharmaceutical solutions of modafinil compounds | |
| ATE265454T1 (de) | Phenyloxazol-1,4-diazabicyclo(3.2.2)nonanderiva e,ihre herstellung und ihre therapeutische verwendung | |
| ITMI20010957A0 (it) | Derivati dell'aoe-emodina e loro impiego nel trattamento di patologieneoplastiche | |
| MXPA03001826A (es) | Derivados de arilpiperazina. | |
| ITTO20000441A0 (it) | Composizione terapeutica per la cura della psoriasi. | |
| BR0205576B1 (pt) | artigo absorvente descartÁvel para ser usado com uma peÇa Íntima tipo tanga. | |
| IT1318516B1 (it) | Derivati 2-amminotetralinici otticamente attivi, procedimenti per laloro preparazione e impiego terapeutico delle corrispondenti | |
| ES1047906Y (es) | Prenda desechable protectora contra las manchas para niños y discapacitados. | |
| ES1047419Y (es) | Camilla perfeccionada para el tratamiento quiropractico. | |
| ES1058584Y (es) | Mecanismo para articulacion y fijacion de pata de mesa. | |
| IT1312082B1 (it) | Derivati morfinoidi, procedimento per la loro preparzione e loroimpiego terapeutico. | |
| ATE538133T1 (de) | Replikin-peptide und ihre verwendungszwecke |